#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6 .
1-1	0-1	6	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Challenges in MSC Translation into Clinical Practice :
2-1	4-14	Challenges	abstract[2]	new[2]	_	_
2-2	15-17	in	abstract[2]	new[2]	_	_
2-3	18-21	MSC	abstract[2]|place|abstract[4]	new[2]|new|new[4]	coref|coref	4-17|4-17
2-4	22-33	Translation	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-5	34-38	into	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-6	39-47	Clinical	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
2-7	48-56	Practice	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
2-8	57-58	:	_	_	_	_

#Text=The Bone Disease Framework
3-1	59-62	The	abstract[8]	new[8]	_	_
3-2	63-67	Bone	person|abstract[8]	new|new[8]	coref	22-1
3-3	68-75	Disease	abstract|abstract[8]	new|new[8]	_	_
3-4	76-85	Framework	abstract[8]	new[8]	_	_

#Text=Other interesting aspects and new perspectives in the field of tissue regeneration and applicative use of MSC are strictly related to their potential to tackle the increase in bone diseases related with the extended life expectancy .
4-1	86-91	Other	abstract[9]	new[9]	_	_
4-2	92-103	interesting	abstract[9]	new[9]	_	_
4-3	104-111	aspects	abstract[9]	new[9]	_	_
4-4	112-115	and	_	_	_	_
4-5	116-119	new	abstract[10]	new[10]	_	_
4-6	120-132	perspectives	abstract[10]	new[10]	_	_
4-7	133-135	in	abstract[10]	new[10]	_	_
4-8	136-139	the	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-9	140-145	field	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-10	146-148	of	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-11	149-155	tissue	abstract[10]|abstract[11]|object|abstract[13]|abstract[14]	new[10]|new[11]|new|new[13]|new[14]	ana|coref|coref|ana|coref|coref|ana|coref|coref	4-22[0_14]|6-16[39_0]|10-24[0_13]|4-22[0_14]|6-16[39_0]|10-24[0_13]|4-22[0_14]|6-16[39_0]|10-24[0_13]
4-12	156-168	regeneration	abstract[10]|abstract[11]|abstract[13]|abstract[14]	new[10]|new[11]|new[13]|new[14]	_	_
4-13	169-172	and	abstract[10]|abstract[11]|abstract[14]	new[10]|new[11]|new[14]	_	_
4-14	173-184	applicative	abstract[10]|abstract[11]|abstract[14]|abstract[15]	new[10]|new[11]|new[14]|new[15]	_	_
4-15	185-188	use	abstract[10]|abstract[11]|abstract[14]|abstract[15]	new[10]|new[11]|new[14]|new[15]	_	_
4-16	189-191	of	abstract[10]|abstract[11]|abstract[14]|abstract[15]	new[10]|new[11]|new[14]|new[15]	_	_
4-17	192-195	MSC	abstract[10]|abstract[11]|abstract[14]|abstract[15]|object	new[10]|new[11]|new[14]|new[15]|giv	coref	11-11
4-18	196-199	are	_	_	_	_
4-19	200-208	strictly	_	_	_	_
4-20	209-216	related	_	_	_	_
4-21	217-219	to	_	_	_	_
4-22	220-225	their	abstract|abstract[18]	giv|new[18]	coref|coref	30-27[302_0]|30-27[302_0]
4-23	226-235	potential	abstract[18]	new[18]	_	_
4-24	236-238	to	_	_	_	_
4-25	239-245	tackle	_	_	_	_
4-26	246-249	the	abstract[19]	new[19]	_	_
4-27	250-258	increase	abstract[19]	new[19]	_	_
4-28	259-261	in	abstract[19]	new[19]	_	_
4-29	262-266	bone	abstract[19]|object|abstract[21]	new[19]|new|new[21]	coref|coref|coref|coref	5-6|5-6[26_21]|5-6|5-6[26_21]
4-30	267-275	diseases	abstract[19]|abstract[21]	new[19]|new[21]	_	_
4-31	276-283	related	_	_	_	_
4-32	284-288	with	_	_	_	_
4-33	289-292	the	abstract[23]	new[23]	_	_
4-34	293-301	extended	abstract[23]	new[23]	_	_
4-35	302-306	life	abstract|abstract[23]	new|new[23]	_	_
4-36	307-317	expectancy	abstract[23]	new[23]	_	_
4-37	318-319	.	_	_	_	_

#Text=Indeed , in many countries bone diseases are becoming a relevant cause of disability , even if they are acute , such as fractures , or chronic , such as osteoporosis and tumours .
5-1	320-326	Indeed	_	_	_	_
5-2	327-328	,	_	_	_	_
5-3	329-331	in	_	_	_	_
5-4	332-336	many	place[24]	new[24]	_	_
5-5	337-346	countries	place[24]	new[24]	_	_
5-6	347-351	bone	object|abstract[26]	giv|giv[26]	ana|coref|ana|coref	5-18[0_26]|6-16|5-18[0_26]|6-16
5-7	352-360	diseases	abstract[26]	giv[26]	_	_
5-8	361-364	are	_	_	_	_
5-9	365-373	becoming	_	_	_	_
5-10	374-375	a	_	_	_	_
5-11	376-384	relevant	_	_	_	_
5-12	385-390	cause	_	_	_	_
5-13	391-393	of	_	_	_	_
5-14	394-404	disability	abstract	new	_	_
5-15	405-406	,	_	_	_	_
5-16	407-411	even	_	_	_	_
5-17	412-414	if	_	_	_	_
5-18	415-419	they	abstract	giv	coref	24-34[258_0]
5-19	420-423	are	_	_	_	_
5-20	424-429	acute	_	_	_	_
5-21	430-431	,	_	_	_	_
5-22	432-436	such	_	_	_	_
5-23	437-439	as	_	_	_	_
5-24	440-449	fractures	event	new	_	_
5-25	450-451	,	_	_	_	_
5-26	452-454	or	_	_	_	_
5-27	455-462	chronic	_	_	_	_
5-28	463-464	,	_	_	_	_
5-29	465-469	such	_	_	_	_
5-30	470-472	as	_	_	_	_
5-31	473-485	osteoporosis	abstract	new	_	_
5-32	486-489	and	_	_	_	_
5-33	490-497	tumours	object	new	_	_
5-34	498-499	.	_	_	_	_

#Text=In any case these pathologies require treatments to enhance the healing and regenerative capacity of bone tissue .
6-1	500-502	In	_	_	_	_
6-2	503-506	any	event[32]	new[32]	coref	15-2[133_32]
6-3	507-511	case	event[32]	new[32]	_	_
6-4	512-517	these	abstract[33]	new[33]	_	_
6-5	518-529	pathologies	abstract[33]	new[33]	_	_
6-6	530-537	require	_	_	_	_
6-7	538-548	treatments	abstract	new	_	_
6-8	549-551	to	_	_	_	_
6-9	552-559	enhance	_	_	_	_
6-10	560-563	the	abstract[35]|abstract[36]	new[35]|new[36]	coref|coref|coref|coref	10-21[81_35]|10-21[82_36]|10-21[81_35]|10-21[82_36]
6-11	564-571	healing	abstract[35]|abstract[36]	new[35]|new[36]	_	_
6-12	572-575	and	abstract[36]	new[36]	_	_
6-13	576-588	regenerative	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-14	589-597	capacity	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-15	598-600	of	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-16	601-605	bone	abstract[36]|abstract[37]|object|object[39]	new[36]|new[37]|giv|giv[39]	coref|coref|coref|coref	7-7|9-31[0_39]|7-7|9-31[0_39]
6-17	606-612	tissue	abstract[36]|abstract[37]|object[39]	new[36]|new[37]|giv[39]	_	_
6-18	613-614	.	_	_	_	_

#Text=The common therapeutic strategies based on bone grafting ( autografts or allografts ) show some disadvantages .
7-1	615-618	The	abstract[40]	new[40]	coref	10-16[79_40]
7-2	619-625	common	abstract[40]	new[40]	_	_
7-3	626-637	therapeutic	abstract[40]	new[40]	_	_
7-4	638-648	strategies	abstract[40]	new[40]	_	_
7-5	649-654	based	_	_	_	_
7-6	655-657	on	_	_	_	_
7-7	658-662	bone	object|object[42]	giv|new[42]	appos|coref|appos|coref	7-10[43_42]|8-6|7-10[43_42]|8-6
7-8	663-671	grafting	object[42]	new[42]	_	_
7-9	672-673	(	_	_	_	_
7-10	674-684	autografts	object[43]	giv[43]	coref	8-1[0_43]
7-11	685-687	or	object[43]	giv[43]	_	_
7-12	688-698	allografts	object[43]	giv[43]	_	_
7-13	699-700	)	_	_	_	_
7-14	701-705	show	_	_	_	_
7-15	706-710	some	abstract[44]	new[44]	coref	10-4[0_44]
7-16	711-724	disadvantages	abstract[44]	new[44]	_	_
7-17	725-726	.	_	_	_	_

#Text=Autografts are limited by the bone volume that can be harvested from the iliac crest and present surgical risks such as bleeding , inflammation , infection , chronic pain , damage at the donor site and morbidity .
8-1	727-737	Autografts	event	giv	coref	9-1
8-2	738-741	are	_	_	_	_
8-3	742-749	limited	_	_	_	_
8-4	750-752	by	_	_	_	_
8-5	753-756	the	quantity[47]	new[47]	_	_
8-6	757-761	bone	object|quantity[47]	giv|new[47]	coref	10-21
8-7	762-768	volume	quantity[47]	new[47]	_	_
8-8	769-773	that	_	_	_	_
8-9	774-777	can	_	_	_	_
8-10	778-780	be	_	_	_	_
8-11	781-790	harvested	_	_	_	_
8-12	791-795	from	_	_	_	_
8-13	796-799	the	object[49]	new[49]	coref	25-23[266_49]
8-14	800-805	iliac	person|object[49]	new|new[49]	coref	25-24
8-15	806-811	crest	object[49]	new[49]	_	_
8-16	812-815	and	_	_	_	_
8-17	816-823	present	abstract[50]	new[50]	coref	21-51[0_50]
8-18	824-832	surgical	abstract[50]	new[50]	_	_
8-19	833-838	risks	abstract[50]	new[50]	_	_
8-20	839-843	such	abstract[50]	new[50]	_	_
8-21	844-846	as	abstract[50]	new[50]	_	_
8-22	847-855	bleeding	abstract[50]	new[50]	_	_
8-23	856-857	,	abstract[50]	new[50]	_	_
8-24	858-870	inflammation	abstract[50]|abstract	new[50]|new	_	_
8-25	871-872	,	abstract[50]	new[50]	_	_
8-26	873-882	infection	abstract[50]|event	new[50]|new	_	_
8-27	883-884	,	abstract[50]	new[50]	_	_
8-28	885-892	chronic	abstract[50]|abstract[53]	new[50]|new[53]	_	_
8-29	893-897	pain	abstract[50]|abstract[53]	new[50]|new[53]	_	_
8-30	898-899	,	abstract[50]	new[50]	_	_
8-31	900-906	damage	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-32	907-909	at	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-33	910-913	the	abstract[50]|abstract[54]|place[56]	new[50]|new[54]|new[56]	coref	25-29[267_56]
8-34	914-919	donor	abstract[50]|abstract[54]|person|place[56]	new[50]|new[54]|new|new[56]	_	_
8-35	920-924	site	abstract[50]|abstract[54]|place[56]	new[50]|new[54]|new[56]	_	_
8-36	925-928	and	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-37	929-938	morbidity	abstract[50]|abstract[54]|event	new[50]|new[54]|new	coref	12-16[99_0]
8-38	939-940	.	_	_	_	_

#Text=Allografts also have some limitations , such as the lack of donors , high costs , the need for sterilization and the risk of infectious agent transmission or immune mediated tissue rejection .
9-1	941-951	Allografts	object	giv	_	_
9-2	952-956	also	_	_	_	_
9-3	957-961	have	_	_	_	_
9-4	962-966	some	abstract[59]|abstract[60]	new[59]|new[60]	coref|coref|coref|coref	10-1[72_59]|10-1[73_60]|10-1[72_59]|10-1[73_60]
9-5	967-978	limitations	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-6	979-980	,	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-7	981-985	such	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-8	986-988	as	abstract[59]|abstract[60]	new[59]|new[60]	_	_
9-9	989-992	the	abstract[59]|abstract[60]|abstract[61]	new[59]|new[60]|new[61]	_	_
9-10	993-997	lack	abstract[59]|abstract[60]|abstract[61]	new[59]|new[60]|new[61]	_	_
9-11	998-1000	of	abstract[59]|abstract[60]|abstract[61]	new[59]|new[60]|new[61]	_	_
9-12	1001-1007	donors	abstract[59]|abstract[60]|abstract[61]|person	new[59]|new[60]|new[61]|new	_	_
9-13	1008-1009	,	abstract[59]|abstract[60]|abstract[61]	new[59]|new[60]|new[61]	_	_
9-14	1010-1014	high	abstract[59]|abstract[60]|abstract[61]|abstract[63]	new[59]|new[60]|new[61]|new[63]	coref	21-49[208_63]
9-15	1015-1020	costs	abstract[59]|abstract[60]|abstract[61]|abstract[63]	new[59]|new[60]|new[61]|new[63]	_	_
9-16	1021-1022	,	abstract[60]	new[60]	_	_
9-17	1023-1026	the	abstract[60]|abstract[64]	new[60]|new[64]	coref	10-12[78_64]
9-18	1027-1031	need	abstract[60]|abstract[64]	new[60]|new[64]	_	_
9-19	1032-1035	for	abstract[60]|abstract[64]	new[60]|new[64]	_	_
9-20	1036-1049	sterilization	abstract[60]|abstract[64]|abstract	new[60]|new[64]|new	_	_
9-21	1050-1053	and	abstract[60]|abstract[64]	new[60]|new[64]	_	_
9-22	1054-1057	the	abstract[60]|abstract[64]|abstract[66]	new[60]|new[64]|new[66]	_	_
9-23	1058-1062	risk	abstract[60]|abstract[64]|abstract[66]	new[60]|new[64]|new[66]	_	_
9-24	1063-1065	of	abstract[60]|abstract[64]|abstract[66]	new[60]|new[64]|new[66]	_	_
9-25	1066-1076	infectious	abstract[60]|abstract[64]|abstract[66]|abstract[68]	new[60]|new[64]|new[66]|new[68]	_	_
9-26	1077-1082	agent	abstract[60]|abstract[64]|abstract[66]|person|abstract[68]	new[60]|new[64]|new[66]|new|new[68]	_	_
9-27	1083-1095	transmission	abstract[60]|abstract[64]|abstract[66]|abstract[68]	new[60]|new[64]|new[66]|new[68]	_	_
9-28	1096-1098	or	abstract[60]|abstract[64]|abstract[66]	new[60]|new[64]|new[66]	_	_
9-29	1099-1105	immune	abstract[60]|abstract[64]|abstract[66]|abstract	new[60]|new[64]|new[66]|new	_	_
9-30	1106-1114	mediated	abstract[60]|abstract[64]|abstract[66]	new[60]|new[64]|new[66]	_	_
9-31	1115-1121	tissue	abstract[60]|abstract[64]|abstract[66]|object|abstract[71]	new[60]|new[64]|new[66]|giv|new[71]	coref|coref	13-15[110_0]|13-15[110_0]
9-32	1122-1131	rejection	abstract[60]|abstract[64]|abstract[66]|abstract[71]	new[60]|new[64]|new[66]|new[71]	_	_
9-33	1132-1133	.	_	_	_	_

#Text=These limitations and disadvantages associated with auto- and allograft approaches indicate a clinical need for alternative therapeutic strategies aimed at bone healing and regeneration .
10-1	1134-1139	These	abstract[72]|abstract[73]	giv[72]|giv[73]	coref|coref	20-1[180_72]|20-1[180_72]
10-2	1140-1151	limitations	abstract[72]|abstract[73]	giv[72]|giv[73]	_	_
10-3	1152-1155	and	abstract[73]	giv[73]	_	_
10-4	1156-1169	disadvantages	abstract[73]|abstract	giv[73]|giv	_	_
10-5	1170-1180	associated	_	_	_	_
10-6	1181-1185	with	_	_	_	_
10-7	1186-1191	auto-	abstract|abstract[77]	new|new[77]	_	_
10-8	1192-1195	and	abstract[77]	new[77]	_	_
10-9	1196-1205	allograft	object|abstract[77]	new|new[77]	_	_
10-10	1206-1216	approaches	abstract[77]	new[77]	_	_
10-11	1217-1225	indicate	_	_	_	_
10-12	1226-1227	a	abstract[78]	giv[78]	coref	21-37[203_78]
10-13	1228-1236	clinical	abstract[78]	giv[78]	_	_
10-14	1237-1241	need	abstract[78]	giv[78]	_	_
10-15	1242-1245	for	abstract[78]	giv[78]	_	_
10-16	1246-1257	alternative	abstract[78]|abstract[79]	giv[78]|giv[79]	_	_
10-17	1258-1269	therapeutic	abstract[78]|abstract[79]	giv[78]|giv[79]	_	_
10-18	1270-1280	strategies	abstract[78]|abstract[79]	giv[78]|giv[79]	_	_
10-19	1281-1286	aimed	_	_	_	_
10-20	1287-1289	at	_	_	_	_
10-21	1290-1294	bone	object|abstract[81]|abstract[82]	giv|giv[81]|giv[82]	coref|coref|coref|coref|coref|coref	11-30|17-22[156_81]|11-30|17-22[156_81]|11-30|17-22[156_81]
10-22	1295-1302	healing	abstract[81]|abstract[82]	giv[81]|giv[82]	_	_
10-23	1303-1306	and	abstract[82]	giv[82]	_	_
10-24	1307-1319	regeneration	abstract[82]|abstract	giv[82]|giv	coref	14-10[121_0]
10-25	1320-1321	.	_	_	_	_

#Text=Thus , new biomaterials and scaffolds , in association with MSC and growth factors , having requirements of biocompatibility , osteoinductive and osteoconductive properties , are investigated to improve bone repair .
11-1	1322-1326	Thus	_	_	_	_
11-2	1327-1328	,	_	_	_	_
11-3	1329-1332	new	substance[84]	new[84]	_	_
11-4	1333-1345	biomaterials	substance[84]	new[84]	_	_
11-5	1346-1349	and	_	_	_	_
11-6	1350-1359	scaffolds	object[85]	new[85]	_	_
11-7	1360-1361	,	object[85]	new[85]	_	_
11-8	1362-1364	in	object[85]	new[85]	_	_
11-9	1365-1376	association	object[85]|abstract[86]	new[85]|new[86]	coref	16-24[143_86]
11-10	1377-1381	with	object[85]|abstract[86]	new[85]|new[86]	_	_
11-11	1382-1385	MSC	object[85]|abstract[86]|abstract|abstract[89]	new[85]|new[86]|giv|new[89]	coref|coref|coref|coref	12-4|12-25[101_89]|12-4|12-25[101_89]
11-12	1386-1389	and	object[85]|abstract[86]|abstract[89]	new[85]|new[86]|new[89]	_	_
11-13	1390-1396	growth	object[85]|abstract[86]|abstract|abstract[89]	new[85]|new[86]|new|new[89]	coref	22-30
11-14	1397-1404	factors	object[85]|abstract[86]|abstract[89]	new[85]|new[86]|new[89]	_	_
11-15	1405-1406	,	_	_	_	_
11-16	1407-1413	having	_	_	_	_
11-17	1414-1426	requirements	abstract[90]	new[90]	_	_
11-18	1427-1429	of	abstract[90]	new[90]	_	_
11-19	1430-1446	biocompatibility	abstract[90]|substance	new[90]|new	_	_
11-20	1447-1448	,	abstract[90]	new[90]	_	_
11-21	1449-1463	osteoinductive	abstract[90]|abstract[92]	new[90]|new[92]	ana	12-8[0_92]
11-22	1464-1467	and	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-23	1468-1483	osteoconductive	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-24	1484-1494	properties	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-25	1495-1496	,	_	_	_	_
11-26	1497-1500	are	_	_	_	_
11-27	1501-1513	investigated	_	_	_	_
11-28	1514-1516	to	_	_	_	_
11-29	1517-1524	improve	_	_	_	_
11-30	1525-1529	bone	object|abstract[94]	giv|new[94]	coref|coref	14-10|14-10
11-31	1530-1536	repair	abstract[94]	new[94]	_	_
11-32	1537-1538	.	_	_	_	_

#Text=The use of MSC is attractive since they can be harvested from the host with minimal morbidity , they can be modified to secrete osteoinductive factors and implanted on an osteoconductive scaffold , to obtain the three key components leading to osteogenesis .
12-1	1539-1542	The	abstract[95]	new[95]	coref	30-14[297_95]
12-2	1543-1546	use	abstract[95]	new[95]	_	_
12-3	1547-1549	of	abstract[95]	new[95]	_	_
12-4	1550-1553	MSC	abstract[95]|object	new[95]|giv	coref	18-6
12-5	1554-1556	is	_	_	_	_
12-6	1557-1567	attractive	_	_	_	_
12-7	1568-1573	since	_	_	_	_
12-8	1574-1578	they	abstract	giv	ana	12-19
12-9	1579-1582	can	_	_	_	_
12-10	1583-1585	be	_	_	_	_
12-11	1586-1595	harvested	_	_	_	_
12-12	1596-1600	from	_	_	_	_
12-13	1601-1604	the	person[98]	new[98]	_	_
12-14	1605-1609	host	person[98]	new[98]	_	_
12-15	1610-1614	with	person[98]	new[98]	_	_
12-16	1615-1622	minimal	person[98]|event[99]	new[98]|giv[99]	coref	28-3[283_99]
12-17	1623-1632	morbidity	person[98]|event[99]	new[98]|giv[99]	_	_
12-18	1633-1634	,	_	_	_	_
12-19	1635-1639	they	abstract	giv	coref	29-17[291_0]
12-20	1640-1643	can	_	_	_	_
12-21	1644-1646	be	_	_	_	_
12-22	1647-1655	modified	_	_	_	_
12-23	1656-1658	to	_	_	_	_
12-24	1659-1666	secrete	_	_	_	_
12-25	1667-1681	osteoinductive	abstract[101]	giv[101]	coref	22-18[219_101]
12-26	1682-1689	factors	abstract[101]	giv[101]	_	_
12-27	1690-1693	and	_	_	_	_
12-28	1694-1703	implanted	_	_	_	_
12-29	1704-1706	on	_	_	_	_
12-30	1707-1709	an	object[102]	new[102]	_	_
12-31	1710-1725	osteoconductive	object[102]	new[102]	_	_
12-32	1726-1734	scaffold	object[102]	new[102]	_	_
12-33	1735-1736	,	_	_	_	_
12-34	1737-1739	to	_	_	_	_
12-35	1740-1746	obtain	_	_	_	_
12-36	1747-1750	the	abstract[103]	new[103]	_	_
12-37	1751-1756	three	abstract[103]	new[103]	_	_
12-38	1757-1760	key	abstract[103]	new[103]	_	_
12-39	1761-1771	components	abstract[103]	new[103]	_	_
12-40	1772-1779	leading	_	_	_	_
12-41	1780-1782	to	_	_	_	_
12-42	1783-1795	osteogenesis	abstract	new	_	_
12-43	1796-1797	.	_	_	_	_

#Text=hMSC have been found in several adult tissues , including the synovial membrane , the adipose tissue , the dental pulp tissue , or in perinatal tissues ( umbilical cord blood and umbilical cord tissue ) .
13-1	1798-1802	hMSC	substance	new	_	_
13-2	1803-1807	have	_	_	_	_
13-3	1808-1812	been	_	_	_	_
13-4	1813-1818	found	_	_	_	_
13-5	1819-1821	in	_	_	_	_
13-6	1822-1829	several	object[106]	new[106]	_	_
13-7	1830-1835	adult	object[106]	new[106]	_	_
13-8	1836-1843	tissues	object[106]	new[106]	_	_
13-9	1844-1845	,	object[106]	new[106]	_	_
13-10	1846-1855	including	object[106]	new[106]	_	_
13-11	1856-1859	the	object[106]|object[108]	new[106]|new[108]	_	_
13-12	1860-1868	synovial	object[106]|abstract|object[108]	new[106]|new|new[108]	_	_
13-13	1869-1877	membrane	object[106]|object[108]	new[106]|new[108]	_	_
13-14	1878-1879	,	object[106]	new[106]	_	_
13-15	1880-1883	the	object[106]|object[110]	new[106]|giv[110]	coref	13-19[112_110]
13-16	1884-1891	adipose	object[106]|abstract|object[110]	new[106]|new|giv[110]	_	_
13-17	1892-1898	tissue	object[106]|object[110]	new[106]|giv[110]	_	_
13-18	1899-1900	,	object[106]	new[106]	_	_
13-19	1901-1904	the	object[106]|object[112]	new[106]|giv[112]	coref	23-27[0_112]
13-20	1905-1911	dental	object[106]|object[112]	new[106]|giv[112]	_	_
13-21	1912-1916	pulp	object[106]|abstract|object[112]	new[106]|new|giv[112]	_	_
13-22	1917-1923	tissue	object[106]|object[112]	new[106]|giv[112]	_	_
13-23	1924-1925	,	object[106]	new[106]	_	_
13-24	1926-1928	or	object[106]	new[106]	_	_
13-25	1929-1931	in	object[106]	new[106]	_	_
13-26	1932-1941	perinatal	object[106]|object[113]	new[106]|new[113]	appos	13-29[116_113]
13-27	1942-1949	tissues	object[106]|object[113]	new[106]|new[113]	_	_
13-28	1950-1951	(	_	_	_	_
13-29	1952-1961	umbilical	substance[115]|object[116]	new[115]|giv[116]	_	_
13-30	1962-1966	cord	object|substance[115]|object[116]	new|new[115]|giv[116]	coref	13-34
13-31	1967-1972	blood	substance[115]|object[116]	new[115]|giv[116]	_	_
13-32	1973-1976	and	object[116]	giv[116]	_	_
13-33	1977-1986	umbilical	object[116]	giv[116]	_	_
13-34	1987-1991	cord	object[116]|object	giv[116]|giv	_	_
13-35	1992-1998	tissue	object[116]	giv[116]	_	_
13-36	1999-2000	)	_	_	_	_
13-37	2001-2002	.	_	_	_	_

#Text=All these cells are suited to therapeutic applications for bone regeneration , by means of two different ways of autologous cells transplantation : ( 1 ) cell therapies without expansion in culture ( one-step procedure ) and ( 2 ) cell therapies with ex vivo expansion .
14-1	2003-2006	All	object[118]	new[118]	coref	14-21[0_118]
14-2	2007-2012	these	object[118]	new[118]	_	_
14-3	2013-2018	cells	object[118]	new[118]	_	_
14-4	2019-2022	are	_	_	_	_
14-5	2023-2029	suited	_	_	_	_
14-6	2030-2032	to	_	_	_	_
14-7	2033-2044	therapeutic	abstract[119]	new[119]	_	_
14-8	2045-2057	applications	abstract[119]	new[119]	_	_
14-9	2058-2061	for	abstract[119]	new[119]	_	_
14-10	2062-2066	bone	abstract[119]|object|abstract[121]	new[119]|giv|giv[121]	coref|coref|coref|coref	16-15[139_0]|21-27[201_121]|16-15[139_0]|21-27[201_121]
14-11	2067-2079	regeneration	abstract[119]|abstract[121]	new[119]|giv[121]	_	_
14-12	2080-2081	,	abstract[119]	new[119]	_	_
14-13	2082-2084	by	abstract[119]	new[119]	_	_
14-14	2085-2090	means	abstract[119]	new[119]	_	_
14-15	2091-2093	of	abstract[119]	new[119]	_	_
14-16	2094-2097	two	abstract[119]|abstract[122]	new[119]|new[122]	_	_
14-17	2098-2107	different	abstract[119]|abstract[122]	new[119]|new[122]	_	_
14-18	2108-2112	ways	abstract[119]|abstract[122]	new[119]|new[122]	_	_
14-19	2113-2115	of	abstract[119]|abstract[122]	new[119]|new[122]	_	_
14-20	2116-2126	autologous	abstract[119]|abstract[122]|event[124]	new[119]|new[122]|new[124]	coref	18-8[161_124]
14-21	2127-2132	cells	abstract[119]|abstract[122]|object|event[124]	new[119]|new[122]|giv|new[124]	coref	15-6
14-22	2133-2148	transplantation	abstract[119]|abstract[122]|event[124]	new[119]|new[122]|new[124]	_	_
14-23	2149-2150	:	_	_	_	_
14-24	2151-2152	(	_	_	_	_
14-25	2153-2154	1	_	_	_	_
14-26	2155-2156	)	_	_	_	_
14-27	2157-2161	cell	place|person[126]	new|new[126]	coref|coref	14-41|14-41
14-28	2162-2171	therapies	person[126]	new[126]	_	_
14-29	2172-2179	without	person[126]	new[126]	_	_
14-30	2180-2189	expansion	person[126]|abstract[127]	new[126]|new[127]	coref	14-44[132_127]
14-31	2190-2192	in	person[126]|abstract[127]	new[126]|new[127]	_	_
14-32	2193-2200	culture	person[126]|abstract[127]|abstract	new[126]|new[127]|new	appos	14-34[129_0]
14-33	2201-2202	(	_	_	_	_
14-34	2203-2211	one-step	abstract[129]	giv[129]	coref	20-13[0_129]
14-35	2212-2221	procedure	abstract[129]	giv[129]	_	_
14-36	2222-2223	)	_	_	_	_
14-37	2224-2227	and	_	_	_	_
14-38	2228-2229	(	abstract[131]	new[131]	_	_
14-39	2230-2231	2	abstract[131]	new[131]	_	_
14-40	2232-2233	)	abstract[131]	new[131]	_	_
14-41	2234-2238	cell	place|abstract[131]	giv|new[131]	coref	18-10
14-42	2239-2248	therapies	abstract[131]	new[131]	_	_
14-43	2249-2253	with	abstract[131]	new[131]	_	_
14-44	2254-2256	ex	abstract[131]|abstract[132]	new[131]|giv[132]	coref	18-13[162_132]
14-45	2257-2261	vivo	abstract[131]|abstract[132]	new[131]|giv[132]	_	_
14-46	2262-2271	expansion	abstract[131]|abstract[132]	new[131]|giv[132]	_	_
14-47	2272-2273	.	_	_	_	_

#Text=In the first case , cells are harvested during surgery .
15-1	2274-2276	In	_	_	_	_
15-2	2277-2280	the	event[133]	giv[133]	_	_
15-3	2281-2286	first	event[133]	giv[133]	_	_
15-4	2287-2291	case	event[133]	giv[133]	_	_
15-5	2292-2293	,	_	_	_	_
15-6	2294-2299	cells	object	giv	coref	22-6[213_0]
15-7	2300-2303	are	_	_	_	_
15-8	2304-2313	harvested	_	_	_	_
15-9	2314-2320	during	_	_	_	_
15-10	2321-2328	surgery	event	new	coref	30-32[305_0]
15-11	2329-2330	.	_	_	_	_

#Text=In 2010 , Jagër et al. , successfully treated more than 100 patients with local bone healing disorders using a biomaterial composite in association with BM aspiration concentrate .
16-1	2331-2333	In	_	_	_	_
16-2	2334-2338	2010	time	new	_	_
16-3	2339-2340	,	_	_	_	_
16-4	2341-2346	Jagër	person	new	_	_
16-5	2347-2349	et	_	_	_	_
16-6	2350-2353	al.	_	_	_	_
16-7	2354-2355	,	_	_	_	_
16-8	2356-2368	successfully	_	_	_	_
16-9	2369-2376	treated	_	_	_	_
16-10	2377-2381	more	_	_	_	_
16-11	2382-2386	than	_	_	_	_
16-12	2387-2390	100	person[138]	new[138]	ana	17-1[0_138]
16-13	2391-2399	patients	person[138]	new[138]	_	_
16-14	2400-2404	with	person[138]	new[138]	_	_
16-15	2405-2410	local	person[138]|object[139]	new[138]|giv[139]	coref	17-13[152_139]
16-16	2411-2415	bone	person[138]|object[139]	new[138]|giv[139]	_	_
16-17	2416-2423	healing	_	_	_	_
16-18	2424-2433	disorders	abstract	new	_	_
16-19	2434-2439	using	_	_	_	_
16-20	2440-2441	a	object[142]	new[142]	_	_
16-21	2442-2453	biomaterial	organization|object[142]	new|new[142]	coref	19-27[175_0]
16-22	2454-2463	composite	object[142]	new[142]	_	_
16-23	2464-2466	in	_	_	_	_
16-24	2467-2478	association	abstract[143]	giv[143]	_	_
16-25	2479-2483	with	abstract[143]	giv[143]	_	_
16-26	2484-2486	BM	abstract[143]|substance|substance[146]	giv[143]|new|new[146]	coref|coref|coref|coref	17-7|17-7[150_146]|17-7|17-7[150_146]
16-27	2487-2497	aspiration	abstract[143]|abstract|substance[146]	giv[143]|new|new[146]	_	_
16-28	2498-2509	concentrate	abstract[143]|substance[146]	giv[143]|new[146]	_	_
16-29	2510-2511	.	_	_	_	_

#Text=They observed that the use of BM concentrate reduced the harvest of autogenous bone by 50 % without negative effects on bone healing .
17-1	2512-2516	They	person	giv	_	_
17-2	2517-2525	observed	_	_	_	_
17-3	2526-2530	that	_	_	_	_
17-4	2531-2534	the	abstract[148]	new[148]	_	_
17-5	2535-2538	use	abstract[148]	new[148]	_	_
17-6	2539-2541	of	abstract[148]	new[148]	_	_
17-7	2542-2544	BM	abstract[148]|substance|substance[150]	new[148]|giv|giv[150]	coref|coref|coref|coref	19-13|21-21[199_150]|19-13|21-21[199_150]
17-8	2545-2556	concentrate	abstract[148]|substance[150]	new[148]|giv[150]	_	_
17-9	2557-2564	reduced	_	_	_	_
17-10	2565-2568	the	event[151]	new[151]	_	_
17-11	2569-2576	harvest	event[151]	new[151]	_	_
17-12	2577-2579	of	event[151]	new[151]	_	_
17-13	2580-2590	autogenous	event[151]|object[152]	new[151]|giv[152]	coref	17-22[0_152]
17-14	2591-2595	bone	event[151]|object[152]	new[151]|giv[152]	_	_
17-15	2596-2598	by	_	_	_	_
17-16	2599-2601	50	quantity[153]	new[153]	_	_
17-17	2602-2603	%	quantity[153]	new[153]	_	_
17-18	2604-2611	without	_	_	_	_
17-19	2612-2620	negative	abstract[154]	new[154]	_	_
17-20	2621-2628	effects	abstract[154]	new[154]	_	_
17-21	2629-2631	on	abstract[154]	new[154]	_	_
17-22	2632-2636	bone	abstract[154]|object|abstract[156]	new[154]|giv|giv[156]	coref|coref|coref|coref	22-22|23-26[245_156]|22-22|23-26[245_156]
17-23	2637-2644	healing	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
17-24	2645-2646	.	_	_	_	_

#Text=The second clinical application of MSC includes the autologous cell transplantation after ex-vivo expansion .
18-1	2647-2650	The	abstract[157]	new[157]	coref	20-5[181_157]
18-2	2651-2657	second	abstract[157]	new[157]	_	_
18-3	2658-2666	clinical	abstract[157]	new[157]	_	_
18-4	2667-2678	application	abstract[157]	new[157]	_	_
18-5	2679-2681	of	abstract[157]	new[157]	_	_
18-6	2682-2685	MSC	abstract[157]|abstract	new[157]|giv	coref	22-4
18-7	2686-2694	includes	_	_	_	_
18-8	2695-2698	the	event[161]	giv[161]	_	_
18-9	2699-2709	autologous	person|event[161]	new|giv[161]	coref	35-5[329_0]
18-10	2710-2714	cell	place|event[161]	giv|giv[161]	coref	19-10
18-11	2715-2730	transplantation	event[161]	giv[161]	_	_
18-12	2731-2736	after	_	_	_	_
18-13	2737-2744	ex-vivo	abstract[162]	giv[162]	_	_
18-14	2745-2754	expansion	abstract[162]	giv[162]	_	_
18-15	2755-2756	.	_	_	_	_

#Text=In 2007 , Nöth et al. , used a cell population from BM aspirate cultured over 12 days under GMP conditions and transplanted them autologously with a tricalcium phosphate biomaterial for the treatment of femoral head necrosis .
19-1	2757-2759	In	_	_	_	_
19-2	2760-2764	2007	time	new	_	_
19-3	2765-2766	,	_	_	_	_
19-4	2767-2771	Nöth	person	new	_	_
19-5	2772-2774	et	_	_	_	_
19-6	2775-2778	al.	_	_	_	_
19-7	2779-2780	,	_	_	_	_
19-8	2781-2785	used	_	_	_	_
19-9	2786-2787	a	abstract[166]	new[166]	_	_
19-10	2788-2792	cell	place|abstract[166]	giv|new[166]	coref	20-24
19-11	2793-2803	population	abstract[166]	new[166]	_	_
19-12	2804-2808	from	_	_	_	_
19-13	2809-2811	BM	abstract|time[168]	giv|new[168]	coref|coref|coref|coref	21-15|21-15[196_168]|21-15|21-15[196_168]
19-14	2812-2820	aspirate	time[168]	new[168]	_	_
19-15	2821-2829	cultured	_	_	_	_
19-16	2830-2834	over	time[169]	new[169]	_	_
19-17	2835-2837	12	time[169]	new[169]	_	_
19-18	2838-2842	days	time[169]	new[169]	_	_
19-19	2843-2848	under	_	_	_	_
19-20	2849-2852	GMP	place|abstract[171]	new|new[171]	ana|coref|ana|coref	19-24[0_171]|21-44|19-24[0_171]|21-44
19-21	2853-2863	conditions	abstract[171]	new[171]	_	_
19-22	2864-2867	and	_	_	_	_
19-23	2868-2880	transplanted	_	_	_	_
19-24	2881-2885	them	abstract	giv	_	_
19-25	2886-2898	autologously	_	_	_	_
19-26	2899-2903	with	_	_	_	_
19-27	2904-2905	a	organization[175]	giv[175]	_	_
19-28	2906-2916	tricalcium	place|organization[175]	new|giv[175]	_	_
19-29	2917-2926	phosphate	person|organization[175]	new|giv[175]	_	_
19-30	2927-2938	biomaterial	organization[175]	giv[175]	_	_
19-31	2939-2942	for	_	_	_	_
19-32	2943-2946	the	abstract[176]	new[176]	coref	24-19[254_176]
19-33	2947-2956	treatment	abstract[176]	new[176]	_	_
19-34	2957-2959	of	abstract[176]	new[176]	_	_
19-35	2960-2967	femoral	abstract[176]|abstract|object[179]	new[176]|new|new[179]	_	_
19-36	2968-2972	head	abstract[176]|object|object[179]	new[176]|new|new[179]	_	_
19-37	2973-2981	necrosis	abstract[176]|object[179]	new[176]|new[179]	_	_
19-38	2982-2983	.	_	_	_	_

#Text=The main limitations for clinical application are the sterility technique , long culture time , high cost , and the mixture of human cell culture medium with fetal bovine serum .
20-1	2984-2987	The	abstract[180]	giv[180]	coref	20-8[183_180]
20-2	2988-2992	main	abstract[180]	giv[180]	_	_
20-3	2993-3004	limitations	abstract[180]	giv[180]	_	_
20-4	3005-3008	for	abstract[180]	giv[180]	_	_
20-5	3009-3017	clinical	abstract[180]|abstract[181]	giv[180]|giv[181]	coref	33-19[322_181]
20-6	3018-3029	application	abstract[180]|abstract[181]	giv[180]|giv[181]	_	_
20-7	3030-3033	are	_	_	_	_
20-8	3034-3037	the	abstract[183]	giv[183]	_	_
20-9	3038-3047	sterility	abstract|abstract[183]	new|giv[183]	_	_
20-10	3048-3057	technique	abstract[183]	giv[183]	_	_
20-11	3058-3059	,	abstract[183]	giv[183]	_	_
20-12	3060-3064	long	abstract[183]|time[185]	giv[183]|new[185]	_	_
20-13	3065-3072	culture	abstract[183]|abstract|time[185]	giv[183]|giv|new[185]	coref	20-23[189_0]
20-14	3073-3077	time	abstract[183]|time[185]	giv[183]|new[185]	_	_
20-15	3078-3079	,	abstract[183]	giv[183]	_	_
20-16	3080-3084	high	abstract[183]|abstract[186]	giv[183]|new[186]	_	_
20-17	3085-3089	cost	abstract[183]|abstract[186]	giv[183]|new[186]	_	_
20-18	3090-3091	,	abstract[183]	giv[183]	_	_
20-19	3092-3095	and	abstract[183]	giv[183]	_	_
20-20	3096-3099	the	abstract[183]|abstract[187]	giv[183]|new[187]	_	_
20-21	3100-3107	mixture	abstract[183]|abstract[187]	giv[183]|new[187]	_	_
20-22	3108-3110	of	abstract[183]|abstract[187]	giv[183]|new[187]	_	_
20-23	3111-3116	human	abstract[183]|abstract[187]|abstract[189]	giv[183]|new[187]|giv[189]	coref	21-30[202_189]
20-24	3117-3121	cell	abstract[183]|abstract[187]|place|abstract[189]	giv[183]|new[187]|giv|giv[189]	_	_
20-25	3122-3129	culture	abstract[183]|abstract[187]|abstract[189]	giv[183]|new[187]|giv[189]	_	_
20-26	3130-3136	medium	abstract[183]|abstract[187]|abstract[189]	giv[183]|new[187]|giv[189]	_	_
20-27	3137-3141	with	_	_	_	_
20-28	3142-3147	fetal	substance[190]	new[190]	_	_
20-29	3148-3154	bovine	substance[190]	new[190]	_	_
20-30	3155-3160	serum	substance[190]	new[190]	_	_
20-31	3161-3162	.	_	_	_	_

#Text=Thus , recently , orthopedic researchers focused their attention on the clinical use of BM aspirate ( BMA ) and BM concentrate ( BMC ) for musculoskeletal regeneration with a “ one-step ” procedure , avoiding the need of additional laboratory stages and GMP facility , thus reducing costs and risks .
21-1	3163-3167	Thus	_	_	_	_
21-2	3168-3169	,	_	_	_	_
21-3	3170-3178	recently	_	_	_	_
21-4	3179-3180	,	_	_	_	_
21-5	3181-3191	orthopedic	person[191]	new[191]	ana	21-8[0_191]
21-6	3192-3203	researchers	person[191]	new[191]	_	_
21-7	3204-3211	focused	_	_	_	_
21-8	3212-3217	their	person|abstract[193]	giv|new[193]	coref|coref	24-3[248_193]|24-3[248_193]
21-9	3218-3227	attention	abstract[193]	new[193]	_	_
21-10	3228-3230	on	_	_	_	_
21-11	3231-3234	the	abstract[194]	new[194]	_	_
21-12	3235-3243	clinical	abstract[194]	new[194]	_	_
21-13	3244-3247	use	abstract[194]	new[194]	_	_
21-14	3248-3250	of	abstract[194]	new[194]	_	_
21-15	3251-3253	BM	abstract[194]|abstract|object[196]	new[194]|giv|giv[196]	appos|coref|appos|coref	21-18[0_196]|21-21|21-18[0_196]|21-21
21-16	3254-3262	aspirate	abstract[194]|object[196]	new[194]|giv[196]	_	_
21-17	3263-3264	(	_	_	_	_
21-18	3265-3268	BMA	object	giv	_	_
21-19	3269-3270	)	_	_	_	_
21-20	3271-3274	and	_	_	_	_
21-21	3275-3277	BM	substance|substance[199]	giv|giv[199]	coref|coref	35-5[330_0]|35-5[330_0]
21-22	3278-3289	concentrate	substance[199]	giv[199]	_	_
21-23	3290-3291	(	_	_	_	_
21-24	3292-3295	BMC	object	new	_	_
21-25	3296-3297	)	_	_	_	_
21-26	3298-3301	for	_	_	_	_
21-27	3302-3317	musculoskeletal	abstract[201]	giv[201]	coref	29-20[293_201]
21-28	3318-3330	regeneration	abstract[201]	giv[201]	_	_
21-29	3331-3335	with	abstract[201]	giv[201]	_	_
21-30	3336-3337	a	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
21-31	3338-3339	“	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
21-32	3340-3348	one-step	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
21-33	3349-3350	”	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
21-34	3351-3360	procedure	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
21-35	3361-3362	,	_	_	_	_
21-36	3363-3371	avoiding	_	_	_	_
21-37	3372-3375	the	abstract[203]	giv[203]	_	_
21-38	3376-3380	need	abstract[203]	giv[203]	_	_
21-39	3381-3383	of	abstract[203]	giv[203]	_	_
21-40	3384-3394	additional	abstract[203]|abstract[205]	giv[203]|new[205]	_	_
21-41	3395-3405	laboratory	abstract[203]|place|abstract[205]	giv[203]|new|new[205]	_	_
21-42	3406-3412	stages	abstract[203]|abstract[205]	giv[203]|new[205]	_	_
21-43	3413-3416	and	abstract[203]	giv[203]	_	_
21-44	3417-3420	GMP	abstract[203]|place|abstract[207]	giv[203]|giv|new[207]	_	_
21-45	3421-3429	facility	abstract[203]|abstract[207]	giv[203]|new[207]	_	_
21-46	3430-3431	,	_	_	_	_
21-47	3432-3436	thus	_	_	_	_
21-48	3437-3445	reducing	_	_	_	_
21-49	3446-3451	costs	abstract[208]	giv[208]	_	_
21-50	3452-3455	and	abstract[208]	giv[208]	_	_
21-51	3456-3461	risks	abstract[208]|abstract	giv[208]|giv	_	_
21-52	3462-3463	.	_	_	_	_

#Text=Bone marrow contains MSC , hematopoietic stem cells , endothelial progenitor cells , other progenitor cells and growth factors , including bone morphogenetic proteins ( BMP ) , platelet-derived growth factor ( PDGF ) , transforming growth factor-β ( TGF-β ) , vascular endothelial growth factor ( VEGF ) , interleukin-8 ( IL-8 ) , and IL-1 receptor antagonist .
22-1	3464-3468	Bone	person|object[211]	giv|new[211]	_	_
22-2	3469-3475	marrow	object[211]	new[211]	_	_
22-3	3476-3484	contains	_	_	_	_
22-4	3485-3488	MSC	place	giv	coref	24-9[251_0]
22-5	3489-3490	,	_	_	_	_
22-6	3491-3504	hematopoietic	object[213]	giv[213]	coref	22-10[216_213]
22-7	3505-3509	stem	object[213]	giv[213]	_	_
22-8	3510-3515	cells	object[213]	giv[213]	_	_
22-9	3516-3517	,	_	_	_	_
22-10	3518-3529	endothelial	object|object[216]	new|giv[216]	coref|coref|coref|coref	22-14[218_216]|22-44|22-14[218_216]|22-44
22-11	3530-3540	progenitor	object|object[216]	new|giv[216]	coref	22-15
22-12	3541-3546	cells	object[216]	giv[216]	_	_
22-13	3547-3548	,	_	_	_	_
22-14	3549-3554	other	object[218]	giv[218]	coref	23-10[238_218]
22-15	3555-3565	progenitor	object|object[218]	giv|giv[218]	_	_
22-16	3566-3571	cells	object[218]	giv[218]	_	_
22-17	3572-3575	and	_	_	_	_
22-18	3576-3582	growth	abstract[219]	giv[219]	coref	23-12[239_219]
22-19	3583-3590	factors	abstract[219]	giv[219]	_	_
22-20	3591-3592	,	_	_	_	_
22-21	3593-3602	including	_	_	_	_
22-22	3603-3607	bone	object|substance[221]	giv|new[221]	coref|coref	23-22|23-22
22-23	3608-3621	morphogenetic	substance[221]	new[221]	_	_
22-24	3622-3630	proteins	substance[221]	new[221]	_	_
22-25	3631-3632	(	_	_	_	_
22-26	3633-3636	BMP	object	new	_	_
22-27	3637-3638	)	_	_	_	_
22-28	3639-3640	,	_	_	_	_
22-29	3641-3657	platelet-derived	abstract[224]	new[224]	coref	22-43[231_224]
22-30	3658-3664	growth	abstract|abstract[224]	giv|new[224]	coref	22-37
22-31	3665-3671	factor	abstract[224]	new[224]	_	_
22-32	3672-3673	(	_	_	_	_
22-33	3674-3678	PDGF	object	new	_	_
22-34	3679-3680	)	_	_	_	_
22-35	3681-3682	,	_	_	_	_
22-36	3683-3695	transforming	_	_	_	_
22-37	3696-3702	growth	abstract|abstract[227]	giv|new[227]	appos|coref|appos|coref	22-40[0_227]|22-45|22-40[0_227]|22-45
22-38	3703-3711	factor-β	abstract[227]	new[227]	_	_
22-39	3712-3713	(	_	_	_	_
22-40	3714-3719	TGF-β	abstract	giv	_	_
22-41	3720-3721	)	_	_	_	_
22-42	3722-3723	,	_	_	_	_
22-43	3724-3732	vascular	abstract[231]	giv[231]	appos	22-48[0_231]
22-44	3733-3744	endothelial	abstract|abstract[231]	giv|giv[231]	_	_
22-45	3745-3751	growth	abstract|abstract[231]	giv|giv[231]	_	_
22-46	3752-3758	factor	abstract[231]	giv[231]	_	_
22-47	3759-3760	(	_	_	_	_
22-48	3761-3765	VEGF	abstract	giv	_	_
22-49	3766-3767	)	_	_	_	_
22-50	3768-3769	,	_	_	_	_
22-51	3770-3783	interleukin-8	abstract	new	appos	22-53
22-52	3784-3785	(	_	_	_	_
22-53	3786-3790	IL-8	abstract	giv	ana	23-1
22-54	3791-3792	)	_	_	_	_
22-55	3793-3794	,	_	_	_	_
22-56	3795-3798	and	_	_	_	_
22-57	3799-3803	IL-1	object[235]	new[235]	_	_
22-58	3804-3812	receptor	object[235]|substance	new[235]|new	_	_
22-59	3813-3823	antagonist	object[235]	new[235]	_	_
22-60	3824-3825	.	_	_	_	_

#Text=It has been identified as an excellent source of cells and growth factors and it has been used with success for bone , cartilage and soft tissue healing .
23-1	3826-3828	It	abstract	giv	ana	23-15
23-2	3829-3832	has	_	_	_	_
23-3	3833-3837	been	_	_	_	_
23-4	3838-3848	identified	_	_	_	_
23-5	3849-3851	as	_	_	_	_
23-6	3852-3854	an	_	_	_	_
23-7	3855-3864	excellent	_	_	_	_
23-8	3865-3871	source	_	_	_	_
23-9	3872-3874	of	_	_	_	_
23-10	3875-3880	cells	object[238]	giv[238]	coref	34-9[325_238]
23-11	3881-3884	and	object[238]	giv[238]	_	_
23-12	3885-3891	growth	object[238]|abstract[239]	giv[238]|giv[239]	_	_
23-13	3892-3899	factors	object[238]|abstract[239]	giv[238]|giv[239]	_	_
23-14	3900-3903	and	_	_	_	_
23-15	3904-3906	it	abstract	giv	_	_
23-16	3907-3910	has	_	_	_	_
23-17	3911-3915	been	_	_	_	_
23-18	3916-3920	used	_	_	_	_
23-19	3921-3925	with	_	_	_	_
23-20	3926-3933	success	abstract[241]	new[241]	coref	26-13[0_241]
23-21	3934-3937	for	abstract[241]	new[241]	_	_
23-22	3938-3942	bone	abstract[241]|object	new[241]|giv	_	_
23-23	3943-3944	,	abstract[241]	new[241]	_	_
23-24	3945-3954	cartilage	abstract[241]|object	new[241]|new	_	_
23-25	3955-3958	and	abstract[241]	new[241]	_	_
23-26	3959-3963	soft	abstract[241]|abstract[245]	new[241]|giv[245]	_	_
23-27	3964-3970	tissue	abstract[241]|object|abstract[245]	new[241]|giv|giv[245]	_	_
23-28	3971-3978	healing	abstract[241]|abstract[245]	new[241]|giv[245]	_	_
23-29	3979-3980	.	_	_	_	_

#Text=We focused our attention on the use of BM-derived MSC in spinal fusion surgical procedures , which is the most definitive treatment performed to restore the structural stability of the spinal column in degenerative and oncological spine diseases .
24-1	3981-3983	We	person	acc	ana	24-3
24-2	3984-3991	focused	_	_	_	_
24-3	3992-3995	our	person|abstract[248]	giv|giv[248]	ana|ana	30-1|30-1
24-4	3996-4005	attention	abstract[248]	giv[248]	_	_
24-5	4006-4008	on	_	_	_	_
24-6	4009-4012	the	abstract[249]	new[249]	_	_
24-7	4013-4016	use	abstract[249]	new[249]	_	_
24-8	4017-4019	of	abstract[249]	new[249]	_	_
24-9	4020-4030	BM-derived	abstract[249]|abstract|place[251]	new[249]|new|giv[251]	coref|coref	29-10[0_251]|29-10[0_251]
24-10	4031-4034	MSC	abstract[249]|place[251]	new[249]|giv[251]	_	_
24-11	4035-4037	in	abstract[249]|place[251]	new[249]|giv[251]	_	_
24-12	4038-4044	spinal	abstract[249]|place[251]|abstract[253]	new[249]|giv[251]|new[253]	_	_
24-13	4045-4051	fusion	abstract[249]|place[251]|abstract|abstract[253]	new[249]|giv[251]|new|new[253]	coref	25-9[262_0]
24-14	4052-4060	surgical	abstract[249]|place[251]|abstract[253]	new[249]|giv[251]|new[253]	_	_
24-15	4061-4071	procedures	abstract[249]|place[251]|abstract[253]	new[249]|giv[251]|new[253]	_	_
24-16	4072-4073	,	_	_	_	_
24-17	4074-4079	which	_	_	_	_
24-18	4080-4082	is	_	_	_	_
24-19	4083-4086	the	abstract[254]	giv[254]	_	_
24-20	4087-4091	most	abstract[254]	giv[254]	_	_
24-21	4092-4102	definitive	abstract[254]	giv[254]	_	_
24-22	4103-4112	treatment	abstract[254]	giv[254]	_	_
24-23	4113-4122	performed	_	_	_	_
24-24	4123-4125	to	_	_	_	_
24-25	4126-4133	restore	_	_	_	_
24-26	4134-4137	the	abstract[255]	new[255]	_	_
24-27	4138-4148	structural	abstract[255]	new[255]	_	_
24-28	4149-4158	stability	abstract[255]	new[255]	_	_
24-29	4159-4161	of	abstract[255]	new[255]	_	_
24-30	4162-4165	the	abstract[255]|object[256]	new[255]|new[256]	_	_
24-31	4166-4172	spinal	abstract[255]|object[256]	new[255]|new[256]	_	_
24-32	4173-4179	column	abstract[255]|object[256]	new[255]|new[256]	_	_
24-33	4180-4182	in	abstract[255]|object[256]	new[255]|new[256]	_	_
24-34	4183-4195	degenerative	abstract[255]|object[256]|abstract[258]	new[255]|new[256]|giv[258]	_	_
24-35	4196-4199	and	abstract[255]|object[256]|abstract[258]	new[255]|new[256]|giv[258]	_	_
24-36	4200-4211	oncological	abstract[255]|object[256]|abstract[258]	new[255]|new[256]|giv[258]	_	_
24-37	4212-4217	spine	abstract[255]|object[256]|object|abstract[258]	new[255]|new[256]|new|giv[258]	coref	30-32
24-38	4218-4226	diseases	abstract[255]|object[256]|abstract[258]	new[255]|new[256]|giv[258]	_	_
24-39	4227-4228	.	_	_	_	_

#Text=Currently , the gold standard stimulus to achieve spinal fusion is autologous bone ( autograft ) , which is commonly harvested from the iliac crest or obtained from the surgical site ( local bone ) .
25-1	4229-4238	Currently	_	_	_	_
25-2	4239-4240	,	_	_	_	_
25-3	4241-4244	the	object[260]	new[260]	coref	25-12[263_260]
25-4	4245-4249	gold	substance|object[260]	new|new[260]	_	_
25-5	4250-4258	standard	object[260]	new[260]	_	_
25-6	4259-4267	stimulus	object[260]	new[260]	_	_
25-7	4268-4270	to	_	_	_	_
25-8	4271-4278	achieve	_	_	_	_
25-9	4279-4285	spinal	substance|abstract[262]	new|giv[262]	coref|coref|coref|coref	26-16|26-16[274_262]|26-16|26-16[274_262]
25-10	4286-4292	fusion	abstract[262]	giv[262]	_	_
25-11	4293-4295	is	_	_	_	_
25-12	4296-4306	autologous	object[263]	giv[263]	appos	25-15[0_263]
25-13	4307-4311	bone	object[263]	giv[263]	_	_
25-14	4312-4313	(	_	_	_	_
25-15	4314-4323	autograft	object	giv	appos	25-33[268_0]
25-16	4324-4325	)	_	_	_	_
25-17	4326-4327	,	_	_	_	_
25-18	4328-4333	which	_	_	_	_
25-19	4334-4336	is	_	_	_	_
25-20	4337-4345	commonly	_	_	_	_
25-21	4346-4355	harvested	_	_	_	_
25-22	4356-4360	from	_	_	_	_
25-23	4361-4364	the	place[266]	giv[266]	_	_
25-24	4365-4370	iliac	person|place[266]	giv|giv[266]	_	_
25-25	4371-4376	crest	place[266]	giv[266]	_	_
25-26	4377-4379	or	_	_	_	_
25-27	4380-4388	obtained	_	_	_	_
25-28	4389-4393	from	_	_	_	_
25-29	4394-4397	the	place[267]	giv[267]	_	_
25-30	4398-4406	surgical	place[267]	giv[267]	_	_
25-31	4407-4411	site	place[267]	giv[267]	_	_
25-32	4412-4413	(	_	_	_	_
25-33	4414-4419	local	object[268]	giv[268]	coref	26-2[269_268]
25-34	4420-4424	bone	object[268]	giv[268]	_	_
25-35	4425-4426	)	_	_	_	_
25-36	4427-4428	.	_	_	_	_

#Text=As autologous bone possesses osteogenic , osteoinductive and osteoconductive abilities ; the success rate of spinal fusion with autograft is high ( up to 95 % ) .
26-1	4429-4431	As	_	_	_	_
26-2	4432-4442	autologous	object[269]	giv[269]	coref	26-19[0_269]
26-3	4443-4447	bone	object[269]	giv[269]	_	_
26-4	4448-4457	possesses	_	_	_	_
26-5	4458-4468	osteogenic	abstract[270]	new[270]	_	_
26-6	4469-4470	,	abstract[270]	new[270]	_	_
26-7	4471-4485	osteoinductive	abstract[270]	new[270]	_	_
26-8	4486-4489	and	abstract[270]	new[270]	_	_
26-9	4490-4505	osteoconductive	abstract[270]	new[270]	_	_
26-10	4506-4515	abilities	abstract[270]	new[270]	_	_
26-11	4516-4517	;	_	_	_	_
26-12	4518-4521	the	abstract[272]	new[272]	_	_
26-13	4522-4529	success	abstract|abstract[272]	giv|new[272]	_	_
26-14	4530-4534	rate	abstract[272]	new[272]	_	_
26-15	4535-4537	of	abstract[272]	new[272]	_	_
26-16	4538-4544	spinal	abstract[272]|substance|abstract[274]	new[272]|giv|giv[274]	coref|coref|coref|coref	29-7|29-7[288_274]|29-7|29-7[288_274]
26-17	4545-4551	fusion	abstract[272]|abstract[274]	new[272]|giv[274]	_	_
26-18	4552-4556	with	abstract[272]|abstract[274]	new[272]|giv[274]	_	_
26-19	4557-4566	autograft	abstract[272]|abstract[274]|abstract	new[272]|giv[274]|giv	coref	27-3
26-20	4567-4569	is	_	_	_	_
26-21	4570-4574	high	_	_	_	_
26-22	4575-4576	(	_	_	_	_
26-23	4577-4579	up	_	_	_	_
26-24	4580-4582	to	_	_	_	_
26-25	4583-4585	95	quantity[276]	new[276]	_	_
26-26	4586-4587	%	quantity[276]	new[276]	_	_
26-27	4588-4589	)	_	_	_	_
26-28	4590-4591	.	_	_	_	_

#Text=However , autograft material is limited in quantity and its quality varies depending on the patient .
27-1	4592-4599	However	_	_	_	_
27-2	4600-4601	,	_	_	_	_
27-3	4602-4611	autograft	object|object[278]	giv|new[278]	coref|coref	28-8|28-8
27-4	4612-4620	material	object[278]	new[278]	_	_
27-5	4621-4623	is	_	_	_	_
27-6	4624-4631	limited	_	_	_	_
27-7	4632-4634	in	_	_	_	_
27-8	4635-4643	quantity	quantity	new	ana	27-10
27-9	4644-4647	and	_	_	_	_
27-10	4648-4651	its	quantity|abstract[281]	giv|new[281]	_	_
27-11	4652-4659	quality	abstract[281]	new[281]	_	_
27-12	4660-4666	varies	_	_	_	_
27-13	4667-4676	depending	_	_	_	_
27-14	4677-4679	on	_	_	_	_
27-15	4680-4683	the	person[282]	new[282]	_	_
27-16	4684-4691	patient	person[282]	new[282]	_	_
27-17	4692-4693	.	_	_	_	_

#Text=Moreover , significant morbidity is associated with bone harvesting , as previously described .
28-1	4694-4702	Moreover	_	_	_	_
28-2	4703-4704	,	_	_	_	_
28-3	4705-4716	significant	event[283]	giv[283]	_	_
28-4	4717-4726	morbidity	event[283]	giv[283]	_	_
28-5	4727-4729	is	_	_	_	_
28-6	4730-4740	associated	_	_	_	_
28-7	4741-4745	with	_	_	_	_
28-8	4746-4750	bone	object|event[285]	giv|new[285]	coref|coref	29-20|29-20
28-9	4751-4761	harvesting	event[285]	new[285]	_	_
28-10	4762-4763	,	_	_	_	_
28-11	4764-4766	as	_	_	_	_
28-12	4767-4777	previously	_	_	_	_
28-13	4778-4787	described	_	_	_	_
28-14	4788-4789	.	_	_	_	_

#Text=Between many alternatives proposed to achieve spinal fusion , MSC are interesting because they can provide osteogenic properties allowing bone regeneration .
29-1	4790-4797	Between	_	_	_	_
29-2	4798-4802	many	abstract[286]	new[286]	ana	29-14[0_286]
29-3	4803-4815	alternatives	abstract[286]	new[286]	_	_
29-4	4816-4824	proposed	_	_	_	_
29-5	4825-4827	to	_	_	_	_
29-6	4828-4835	achieve	_	_	_	_
29-7	4836-4842	spinal	substance|abstract[288]	giv|giv[288]	coref|coref|coref|coref	30-30[0_288]|32-16|30-30[0_288]|32-16
29-8	4843-4849	fusion	abstract[288]	giv[288]	_	_
29-9	4850-4851	,	_	_	_	_
29-10	4852-4855	MSC	object	giv	coref	30-17
29-11	4856-4859	are	_	_	_	_
29-12	4860-4871	interesting	_	_	_	_
29-13	4872-4879	because	_	_	_	_
29-14	4880-4884	they	abstract	giv	_	_
29-15	4885-4888	can	_	_	_	_
29-16	4889-4896	provide	_	_	_	_
29-17	4897-4907	osteogenic	abstract[291]	giv[291]	_	_
29-18	4908-4918	properties	abstract[291]	giv[291]	_	_
29-19	4919-4927	allowing	_	_	_	_
29-20	4928-4932	bone	object|abstract[293]	giv|giv[293]	coref|coref|coref|coref	30-27|30-27[301_293]|30-27|30-27[301_293]
29-21	4933-4945	regeneration	abstract[293]	giv[293]	_	_
29-22	4946-4947	.	_	_	_	_

#Text=We recently published a descriptive systematic literature review in order to understand if the use of MSC may represent a valid strategy to facilitate and accelerate bone regeneration and fusion during spine surgery .
30-1	4948-4950	We	person	giv	ana	31-4
30-2	4951-4959	recently	_	_	_	_
30-3	4960-4969	published	_	_	_	_
30-4	4970-4971	a	abstract[296]	new[296]	coref	31-2[306_296]
30-5	4972-4983	descriptive	abstract[296]	new[296]	_	_
30-6	4984-4994	systematic	abstract[296]	new[296]	_	_
30-7	4995-5005	literature	abstract|abstract[296]	new|new[296]	_	_
30-8	5006-5012	review	abstract[296]	new[296]	_	_
30-9	5013-5015	in	_	_	_	_
30-10	5016-5021	order	_	_	_	_
30-11	5022-5024	to	_	_	_	_
30-12	5025-5035	understand	_	_	_	_
30-13	5036-5038	if	_	_	_	_
30-14	5039-5042	the	abstract[297]	giv[297]	_	_
30-15	5043-5046	use	abstract[297]	giv[297]	_	_
30-16	5047-5049	of	abstract[297]	giv[297]	_	_
30-17	5050-5053	MSC	abstract[297]|event	giv[297]|giv	coref	32-6
30-18	5054-5057	may	_	_	_	_
30-19	5058-5067	represent	_	_	_	_
30-20	5068-5069	a	abstract[299]	new[299]	_	_
30-21	5070-5075	valid	abstract[299]	new[299]	_	_
30-22	5076-5084	strategy	abstract[299]	new[299]	_	_
30-23	5085-5087	to	_	_	_	_
30-24	5088-5098	facilitate	_	_	_	_
30-25	5099-5102	and	_	_	_	_
30-26	5103-5113	accelerate	_	_	_	_
30-27	5114-5118	bone	object|abstract[301]|abstract[302]	giv|giv[301]|giv[302]	_	_
30-28	5119-5131	regeneration	abstract[301]|abstract[302]	giv[301]|giv[302]	_	_
30-29	5132-5135	and	abstract[302]	giv[302]	_	_
30-30	5136-5142	fusion	abstract[302]|abstract	giv[302]|giv	coref	32-16[316_0]
30-31	5143-5149	during	_	_	_	_
30-32	5150-5155	spine	object|event[305]	giv|giv[305]	_	_
30-33	5156-5163	surgery	event[305]	giv[305]	_	_
30-34	5164-5165	.	_	_	_	_

#Text=In this review we selected and analyzed 50 relevant papers , stratified according to preclinical studies and clinical trials .
31-1	5166-5168	In	_	_	_	_
31-2	5169-5173	this	abstract[306]	giv[306]	_	_
31-3	5174-5180	review	abstract[306]	giv[306]	_	_
31-4	5181-5183	we	person	giv	_	_
31-5	5184-5192	selected	_	_	_	_
31-6	5193-5196	and	_	_	_	_
31-7	5197-5205	analyzed	_	_	_	_
31-8	5206-5208	50	object[308]	new[308]	_	_
31-9	5209-5217	relevant	object[308]	new[308]	_	_
31-10	5218-5224	papers	object[308]	new[308]	_	_
31-11	5225-5226	,	_	_	_	_
31-12	5227-5237	stratified	_	_	_	_
31-13	5238-5247	according	_	_	_	_
31-14	5248-5250	to	_	_	_	_
31-15	5251-5262	preclinical	abstract[309]|person[310]	new[309]|new[310]	coref|ana|coref|ana	33-3[317_309]|35-3[0_310]|33-3[317_309]|35-3[0_310]
31-16	5263-5270	studies	abstract[309]|person[310]	new[309]|new[310]	_	_
31-17	5271-5274	and	person[310]	new[310]	_	_
31-18	5275-5283	clinical	person[310]|event[311]	new[310]|new[311]	_	_
31-19	5284-5290	trials	person[310]|event[311]	new[310]|new[311]	_	_
31-20	5291-5292	.	_	_	_	_

#Text=Preclinical published data showed that MSC have the potential to achieve , facilitate and accelerate spinal fusion .
32-1	5293-5304	Preclinical	abstract[312]	new[312]	_	_
32-2	5305-5314	published	abstract[312]	new[312]	_	_
32-3	5315-5319	data	abstract[312]	new[312]	_	_
32-4	5320-5326	showed	_	_	_	_
32-5	5327-5331	that	_	_	_	_
32-6	5332-5335	MSC	object	giv	_	_
32-7	5336-5340	have	_	_	_	_
32-8	5341-5344	the	abstract[314]	new[314]	_	_
32-9	5345-5354	potential	abstract[314]	new[314]	_	_
32-10	5355-5357	to	_	_	_	_
32-11	5358-5365	achieve	_	_	_	_
32-12	5366-5367	,	_	_	_	_
32-13	5368-5378	facilitate	_	_	_	_
32-14	5379-5382	and	_	_	_	_
32-15	5383-5393	accelerate	_	_	_	_
32-16	5394-5400	spinal	substance|abstract[316]	giv|giv[316]	coref|coref|coref|coref	34-12|34-12[327_316]|34-12|34-12[327_316]
32-17	5401-5407	fusion	abstract[316]	giv[316]	_	_
32-18	5408-5409	.	_	_	_	_

#Text=However , preclinical studies on animal models indicated that some barriers remain prior to this therapy translation into the clinical application .
33-1	5410-5417	However	_	_	_	_
33-2	5418-5419	,	_	_	_	_
33-3	5420-5431	preclinical	abstract[317]	giv[317]	coref	34-4[323_317]
33-4	5432-5439	studies	abstract[317]	giv[317]	_	_
33-5	5440-5442	on	abstract[317]	giv[317]	_	_
33-6	5443-5449	animal	abstract[317]|object[318]	giv[317]|new[318]	_	_
33-7	5450-5456	models	abstract[317]|object[318]	giv[317]|new[318]	_	_
33-8	5457-5466	indicated	_	_	_	_
33-9	5467-5471	that	_	_	_	_
33-10	5472-5476	some	abstract[319]	new[319]	_	_
33-11	5477-5485	barriers	abstract[319]	new[319]	_	_
33-12	5486-5492	remain	_	_	_	_
33-13	5493-5498	prior	_	_	_	_
33-14	5499-5501	to	_	_	_	_
33-15	5502-5506	this	abstract[321]	new[321]	_	_
33-16	5507-5514	therapy	abstract|abstract[321]	new|new[321]	_	_
33-17	5515-5526	translation	abstract[321]	new[321]	_	_
33-18	5527-5531	into	abstract[321]	new[321]	_	_
33-19	5532-5535	the	abstract[321]|abstract[322]	new[321]|giv[322]	_	_
33-20	5536-5544	clinical	abstract[321]|abstract[322]	new[321]|giv[322]	_	_
33-21	5545-5556	application	abstract[321]|abstract[322]	new[321]|giv[322]	_	_
33-22	5557-5558	.	_	_	_	_

#Text=So far , few published clinical studies employ stem cells for spinal fusion .
34-1	5559-5561	So	_	_	_	_
34-2	5562-5565	far	_	_	_	_
34-3	5566-5567	,	_	_	_	_
34-4	5568-5571	few	abstract[323]	giv[323]	_	_
34-5	5572-5581	published	abstract[323]	giv[323]	_	_
34-6	5582-5590	clinical	abstract[323]	giv[323]	_	_
34-7	5591-5598	studies	abstract[323]	giv[323]	_	_
34-8	5599-5605	employ	_	_	_	_
34-9	5606-5610	stem	plant|object[325]	new|giv[325]	coref|coref	35-12[331_325]|35-12[331_325]
34-10	5611-5616	cells	object[325]	giv[325]	_	_
34-11	5617-5620	for	object[325]	giv[325]	_	_
34-12	5621-5627	spinal	object[325]|substance|abstract[327]	giv[325]|giv|giv[327]	coref|coref	35-17[0_327]|35-17[0_327]
34-13	5628-5634	fusion	object[325]|abstract[327]	giv[325]|giv[327]	_	_
34-14	5635-5636	.	_	_	_	_

#Text=Most of them used concentrated autologous BM as primary source of stem cells and they showed fusion results ranging from 87 % to 92.3 % in a total of 297 patients .
35-1	5637-5641	Most	_	_	_	_
35-2	5642-5644	of	_	_	_	_
35-3	5645-5649	them	person	giv	ana	35-15
35-4	5650-5654	used	_	_	_	_
35-5	5655-5667	concentrated	person[329]|substance[330]	giv[329]|giv[330]	_	_
35-6	5668-5678	autologous	person[329]|substance[330]	giv[329]|giv[330]	_	_
35-7	5679-5681	BM	substance[330]	giv[330]	_	_
35-8	5682-5684	as	_	_	_	_
35-9	5685-5692	primary	_	_	_	_
35-10	5693-5699	source	_	_	_	_
35-11	5700-5702	of	_	_	_	_
35-12	5703-5707	stem	object[331]	giv[331]	_	_
35-13	5708-5713	cells	object[331]	giv[331]	_	_
35-14	5714-5717	and	_	_	_	_
35-15	5718-5722	they	person	giv	_	_
35-16	5723-5729	showed	_	_	_	_
35-17	5730-5736	fusion	abstract|abstract[334]	giv|new[334]	_	_
35-18	5737-5744	results	abstract[334]	new[334]	_	_
35-19	5745-5752	ranging	_	_	_	_
35-20	5753-5757	from	_	_	_	_
35-21	5758-5760	87	quantity[335]	new[335]	_	_
35-22	5761-5762	%	quantity[335]	new[335]	_	_
35-23	5763-5765	to	quantity[335]	new[335]	_	_
35-24	5766-5770	92.3	quantity[335]|quantity[336]	new[335]|new[336]	_	_
35-25	5771-5772	%	quantity[335]|quantity[336]	new[335]|new[336]	_	_
35-26	5773-5775	in	_	_	_	_
35-27	5776-5777	a	person[337]	new[337]	_	_
35-28	5778-5783	total	person[337]	new[337]	_	_
35-29	5784-5786	of	person[337]	new[337]	_	_
35-30	5787-5790	297	person[337]	new[337]	_	_
35-31	5791-5799	patients	person[337]	new[337]	_	_
35-32	5800-5801	.	_	_	_	_
